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Abstract
Background: Prior analyses beyond clinical trials are yet to evaluate the projected lifetime benefit of apixaban
treatment compared to low-molecular-weight heparin (LMWH)/vitamin K antagonist (VKA) for treatment of venous
thromboembolism (VTE) and prevention of recurrences. The objective of this study is to assess the cost-effectiveness of
initial plus extended treatment with apixaban versus LMWH/VKA for either initial treatment only or initial plus extended
treatment.
Methods: A Markov cohort model was developed to evaluate the lifetime clinical and economic impact of treatment
of VTE and prevention of recurrences with apixaban (starting at 10 mg BID for 1 week, then 5 mg BID for 6 months,
then 2.5 mg BID for an additional 12 months) versus LMWH/VKA for 6 months and either no further treatment or
extended treatment with VKA for an additional 12 months. Clinical event rates to inform the model were taken from
the AMPLIFY and AMPLIFY-EXT trials and a network meta-analysis. Background mortality rates, costs, and utilities were
obtained from published sources. The analysis was conducted from the perspective of the United Kingdom National
Health Service. The evaluated outcomes included the number of events avoided in a 1000-patient cohort, total costs,
life-years, quality-adjusted life-years (QALYs), and cost per QALY gained.
Results: Initial plus extended treatment with apixaban was superior to both treatment durations of LMWH/VKA in
reducing the number of bleeding events, and was superior to initial LMWH/VKA for 6 months followed by no therapy,
in reducing VTE recurrences. Apixaban treatment was cost-effective compared to 6-month treatment with LMWH/VKA
at an incremental cost-effectiveness ratio (ICER) of £6692 per QALY. When initial LMWH/VKA was followed by further
VKA therapy for an additional 12 months (i.e., total treatment duration of 18 months), apixaban was cost-effective at an
ICER of £8528 per QALY gained. Sensitivity analysis suggested these findings were robust over a wide range of inputs
and scenarios for the model.
Conclusions: In the UK, initial plus extended treatment with apixaban for treatment of VTE and prevention of
recurrences appears to be economical and a clinically effective alternative to LMWH/VKA, whether used for initial or
initial plus extended treatment.
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Background
Deep vein thrombosis (DVT) and pulmonary embolism
(PE) collectively constitute venous thromboembolism
(VTE), the third most prevalent cardiovascular disease,
[1] of which more than one million events occur annu-
ally among Europeans [2]. This clinical burden is
reflected in the high total cost of VTE management,
which in the United Kingdom (UK), for example, has
been estimated at £640 million annually in direct and in-
direct costs (2004 estimate) [3]. A key determinant of
this substantial economic burden is the need for
medium- or long-term administration of anticoagulant
therapy to treat acute VTE and help to prevent its recur-
rence. Specifically, guidelines recommend at least
3 months of anticoagulant treatment for VTE caused by
a reversible risk factor, with the duration of treatment
being long-term to at least 6 months in the case of un-
provoked VTE or indefinitely in patients with certain
risk factors (e.g., active cancer or the presence of other
hypercoaguable conditions). Also, extended treatment
durations are often chosen where patients have recur-
rent thromboses or a low risk of bleeding [4–7].
Until recently, the only available and recommended an-
ticoagulants for use in VTE were heparins (e.g., low-
molecular-weight heparin [LMWH]) or fondaparinux to
initiate treatment, and vitamin K antagonists (VKAs) such
as warfarin or acenocumerol to continue treatment and
subsequent prevention of recurrence [8]. Use of these
drugs is limited and complicated by their narrow thera-
peutic range and the burdensome requirement to monitor
their anticoagulant effect by regularly measuring the inter-
national normalized ratio of the prothrombin time [9].
VKAs also have many drug-drug and drug-food interac-
tions, which in turn affect international normalized ratio
control and patients’ health-related quality of life [10].
The introduction of the drug apixaban, one of the new
class of so-called direct oral anticoagulants (DOACs),
could address many of the difficulties associated with
VKA treatment, since by comparison, it exhibits non-
inferiority in reducing VTE events, has a superior bleeding
profile and does not impose a monitoring burden [11].
Evidence supporting this idea includes data from two
double-blind randomised controlled trials that have stud-
ied apixaban. The AMPLIFY study was a non-inferiority
trial that compared apixaban (10 mg twice a day [BID] for
7 days followed by 5 mg BID) to 7-day LMWH with con-
current initiation of VKA for 6 months in patients with
acute VTE [12]. Apixaban provided a significant and clin-
ically relevant reduction in major bleeding versus
LWMH/VKA with a non-inferior reduction in recurrent
VTE events [12]. The second trial, AMPLIFY-EXT, was in
patients with VTE who had completed 6 to 12 months of
anticoagulation therapy and in whom there was clinical
equipoise as to whether to continue or stop therapy. It
was a placebo-controlled superiority trial that assessed
two doses of apixaban (2.5 mg and 5 mg BID) over a 12-
month period and found that the drug significantly re-
duced the risk of recurrent VTE and VTE-related without
increasing the rate of major or clinically relevant non-
major bleeding [13].
A key question now is whether or not these clinical
advantages of apixaban would be associated with any
significant changes in health economic outcomes. This
study aimed to address this evidence gap by using eco-
nomic modelling to assess the cost-effectiveness of treat-
ment and prevention of recurrences of VTE with
apixaban versus LMWH/VKA. To do this, it compared
the use of apixaban for an initial and long-term (6-
month) treatment period plus a subsequent 12-month
extended treatment period (hereafter referred to as “ini-
tial plus extended apixaban”) with the use of initial
treatment with LMWH, in combination with long-term
treatment for 6 months with VKA, as in the AMPLIFY
and AMPLIFY-EXT studies (and hereafter referred to as
“initial LMWH/VKA). Apixaban was also compared to
initial treatment with LMWH, long-term and extended
for a total of 18 months with VKA (hereafter referred to
as “initial plus extended LMWH/VKA”).
Methods
The current study aimed to estimate the long-term clin-
ical and economic outcomes for patients experiencing
VTE, from the perspective of the UK National Health
Service (NHS). To conduct this analysis, a Markov co-
hort approach was chosen as this approach has been
used in previous evaluations for VTE and found to ad-
equately capture the disease and consequences of treat-
ment [14–16]. Such a model conceptualises the course
of a disease by describing what might happen to a theor-
etical cohort of patients who spend time in various
health ‘states’ that collectively represent the important
clinical and economic consequences of the condition
[17–19]. These states are mutually exclusive, and so a
patient can be in only one of them at any given point.
However, a patient can also move between health states
through experiencing specific disease events, as long no
more than one such transition occurs within each model
‘cycle’ – a fixed duration that recurs without interruption
for as long as the model operates [17–19]. Crucially, the
duration chosen for this cycle should reflect the disease
being modelled: it needs be long enough to capture the
full implications of a disease event but also sufficiently
short that there would probably be only a single event in
one cycle [17–19]. The chances that patients will move
between health states during a cycle (the so-called ‘tran-
sition probabilities’) are a key design feature of the
model [17–19]. With each cycle, the patients accrue
(and the model computes) health care costs, life-years
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(LYs), and quality-adjusted life-years (QALYs) at rates
dependent upon their health states. The model was de-
veloped in Microsoft Excel (Fig. 1), as this is a common
platform for most users, and operated (using UK cost
and outcome data to generate results, where possible).
An example of the technical calculations included in the
model is provided in Additional file 1.
In this study, all patients in the cohort were assumed
to begin in the index VTE health state, having just expe-
rienced a VTE event and commenced anticoagulant
treatment. Patients could move to other states or remain
in the current state during each subsequent model cycle.
Specifically, the states were either permanent (e.g., non-
fatal intracranial bleed and chronic thromboembolic pul-
monary hypertension [CTEPH]), in which case, patients
remained in the health state without experiencing fur-
ther events until death, or transient (e.g., recurrent
DVT), such that patients spent a temporary period in
the health state. The model used a 3-month cycle length,
a duration consistent with those in previous VTE models
[14, 15]. During each cycle, the cohort was subjected to
competing risks of the following events: recurrent VTE,
major bleeds, clinically relevant non-major (CRNM)
bleeds, and death. Recurrent VTE events were classified
as non-fatal recurrent PE, non-fatal recurrent DVT, or
VTE-related death. Major bleeding events were classified
as fatal and or non-fatal; and those that were non-fatal
were further segregated between intracranial (IC) bleeds
and non-IC bleeds. Patients experiencing a PE were at
risk of CTEPH, whilst those experiencing a DVT were at
risk of post-thrombotic syndrome (PTS), with risks for
both events being independent of treatment. The model
took into account only severe PTS, in view of published
evidence suggesting that mild or moderate PTS had little
effect on patients’ healthcare costs or self-assessment of
their state of health [20, 21]. Patients were also at risk of
treatment discontinuation, either as a result of major
bleeding or because of adverse events unrelated to
bleeding, in which case patients would move to ‘VTE
off-treatment’ health states, where they would be ex-
posed to the same events but at higher risk levels, in line
with the fact that they were not receiving anticoagulant
treatment. The model steps through multiple cycles until
all patients from the initial cohort are dead.
Changes in treatment were modelled upon the occur-
rence of each event; but these treatment changes did not
have an effect on subsequent transition risks in the
model, only on costs and utilities. Patients experiencing
a recurrent VTE event whilst on treatment were as-
sumed to receive an additional 6 months of their current
anticoagulation treatment. Patients currently off treat-
ment were assumed to receive 6-month treatment with
LMWH/VKA upon the occurrence of a recurrent VTE.
Patients experiencing a non-fatal IC bleed were assumed
to discontinue treatment permanently. Of the patients
who experienced a non-fatal non-IC major bleed, 52.7%
were assumed to discontinue treatment permanently, as
calculated from secondary analysis of AMPLIFY using
the number of treatment discontinuations due to major
bleeding [12]. For the remainder of patients who experi-
enced a non-fatal non-IC major bleed, it was assumed
that treatment would be interrupted for 14 days before
anticoagulant treatment was resumed. Patients experien-
cing a CRNM bleed were assumed to have their anti-
coagulant therapy interrupted for 2 days and then
resumed thereafter for the remaining intended duration
of treatment.
Treatment
Treatment alternatives within the model mirrored those















Background mortality adjusted for excess long-term mortality 
associated with CTEPH
Fatal major bleeding events and background mortality (adjusted for 
excess long-term mortality associated with IC bleed [intracranial]) 
Fig. 1 Model Diagram. *Patients in the off-treatment health state can
experience the same events as patients in the on-treatment health
states but at different risk levels. This diagram presents all potential
health states that a patient may occupy while in the model. Arrows
indicate potential health state transitions of patients. Dark Grey health
states denote the treatment or originating health states. Patients are
exposed to risks of recurrent VTE, CRNM bleed, CTEPH, major bleed,
and death. The light grey health states (Recurrent VTE and CRNM
bleed) are transient health states; that is, patients spend a temporary
amount of time in this health state, and then return to their originating
health state. CTEPH and Major bleeds are semi-absorbing health states;
where patients do not experience any further events and remain in this
health state until death. Major bleed is semi-absorbing if it is an IC
bleed. If it is a non-IC bleed, it is a transient health state. PTS is modelled
in the background and it is not a separate health state, but patients
accrue expected costs and quality of life utility decrements associated
with PTS while alive
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with apixaban was initiated at a dose of 10 mg BID for
1 week, then 5 mg BID long-term treatment for the re-
mainder of the first 6 months, followed by extended
treatment with 2.5 mg BID for an additional 12 months.
This regimen was compared to LMWH initiated for at
least 5 days, with dose-adjusted VKA therapy beginning
concomitantly and continued for 6 months of long-term
treatment followed either by no further extended treat-
ment (as per AMPLIFY [12] and AMPLIFY-EXT [13])
or by an additional 12 months of extended treatment
with dose-adjusted VKA.
The base-case analysis therefore compared the following:
 Initial plus extended treatment with apixaban for
18 months, versus initial treatment with LMWH/
VKA for 6 months
 Initial plus extended treatment with apixaban for
18 months, versus initial plus extended treatment
with LMWH/VKA for 18 months.
Population
The population that required anticoagulation for the
treatment and prevention of VTE recurrence consisted
of 58.7% males and 41.3% females and entered the
model with a mean age of 56.9 years [12]. It was as-
sumed that 65.8% of patients, had experienced an initial
DVT and 34.2% had experienced a PE [12]. These pa-
tient characteristics match those of the AMPLIFY clin-
ical trial.
Risk of clinical events
Table 1 presents the underlying time-dependent risks for
each of the clinical events modelled for patients treated
with apixaban. As suggested by clinical experts to the
National Institute for Health and Care Excellence, there
is no biological reason to believe that the treatment ef-
fects of anticoagulant therapy change over time, [22]
therefore, justifying the application of constant relative
treatment effects for VKA and placebo versus apixaban
in the model, as presented in Table 2. Clinical event
rates for recurrent VTE and VTE-related death, major
bleeds, CRNM bleeds, and treatment discontinuation
were obtained from secondary analysis of the AMPLIFY
trial for the initial and long-term period (0–6 months)
and the AMPLIFY-EXT trial for the extended period
(beyond 6 months). Time-dependent risks of recurrent
VTE and VTE-related death for untreated patients after
18 months (i.e., beyond the point to which patients were
observed in the trials) was based on a prospective cohort
study that followed patients with VTE over 10 years after
treatment cessation [23]. The event rate for CTEPH was
based on a prospective study that evaluated patients with
PE treated with heparin infusion for 1 week followed by
oral anticoagulation for 1 year. The study found that
four of the 320 patients with PE developed CTEPH over
a period of 2.1 years [24]. The risk of severe PTS was
obtained from a prospective follow-up study of DVT pa-
tients who were treated with an initial course of LMWH
followed by at least 3 months of oral anticoagulant ther-
apy. The cumulative incidence of severe PTS was found
to be 8.1% at 5 years, [25] consistent with more recently
published estimates [26]. It was therefore assumed that
there would be a constant risk of PTS of 8.1% in patients
who had an index DVT, similar to the approach used in
earlier models [16].
Treatment effects for VKA compared with apixaban
beyond the first 6 months in the form of relative risks
were estimated by conducting a network meta-analysis
(NMA) of clinical trials that had assessed extended
anticoagulation treatment. Specifically, the NMA was
conducted to examine the relative efficacy and safety of
apixaban, rivaroxaban, dabigatran, aspirin, and warfarin
(standard- and low-dose) in patients receiving extended
treatment following initial treatment for an acute DVT
and/or PE event. The effects for apixaban and no treat-
ment were obtained from AMPLIFY-EXT, whilst those
for VKA were obtained from the following trials: REM-
EDY, [27] LAFIT, [4] WODIT DVT, [28] and WODIT
PE [29]. The data derived from the NMA are presented
in the Additional file 2.
After the first 18 months in the model, the rates of
major bleeding and CRNM bleeding were increased by a
factor of 1.97 per decade of life to account for increased
risk due to ageing [30]. These adjustments were not re-
quired before the first 18 months since rates for this ini-
tial period were based directly on the observed data
from the AMPLIFY study and so would automatically
reflect any added risk from ageing.
Mortality
Background mortality was modelled based on age- and
sex-specific UK life tables [31]. Hazard ratios reflecting
the increased mortality associated with PE and DVT (ex-
cluding mortality due to bleeding and VTE recurrence,
as these were explicitly modelled), CTEPH, and IC
bleeds were applied to the background mortality rate to
reflect the increased risk of death. These hazard ratios
were taken from retrospective studies [32–34].
Costs
Costs and sources are detailed in Table 3 and reflect
2011/2012 values. When prices for these years were not
available, inflation rates were applied to the source data
using the Pay & Prices index [35]. Anticoagulation costs
were taken from the British National Formulary and
electronic Market Information Tool [36, 37]. Adminis-
tration and monitoring costs were based on a National
Institute for Health and Care Excellence appraisal for
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rivaroxaban [16] and were calculated from the Personal
Social Services Research Unit and NHS reference costs
[35, 38]. It was assumed that six international normal-
ized ratio monitoring visits would be required in the first
3 months followed by three visits every subsequent
3 months [39]. Event costs were separated into acute-
care costs, which were applied at the time of the event,
and maintenance costs. Maintenance costs were speci-
fied for two periods: the first 3 months after the acute
event, and beyond the first 3 months following the
event. Maintenance costs were applied only to those pa-
tients who experienced an IC bleed or CTEPH event.
Patients experiencing all other events were exposed only
to acute-care costs. These costs, along with those of
treatment, were taken from NHS reference costs [38].
Utilities
In order to generate QALYs, a key measure in the ana-
lysis, health state utilities were required as inputs for the
model. Utilities represent an individual’s preferences for
states of health, measured on a scale of 0 to 1, with 0
representing states of health equivalent to death, and a
value of 1 indicating perfect health. On this basis, a util-
ity for a given health state can be combined with the
number of life-years a patient spends in that state to de-
rive QALYs – an overall measure of both the duration
and quality of life the patient experiences. Accordingly,
the health states in the model vary with regard to their
associated outcomes and utilities, and these are automat-
ically updated by the model when patients experience
events that occur and therefore move between health
states. On entering the model all patients in the cohort
had a baseline utility of 0.825 (0.003) applied, based
upon a UK population-average score [40]. On the occur-
rence of a transient event (such as a PE, DVT, non-IC
bleed, CRNM bleed or severe PTS) a utility decrement
associated with that event was subtracted from the base-
line utility, to reflect the negative impact of the episode
on the patient’s health-related quality of life [10, 20, 41, 42].
The pre-specified durations for which these events were as-
sumed to impair health-related quality of life were based on
expert opinion and published literature [43, 44]. On the oc-
currence of a permanent event (such as an intracranial








0–3 months 1.71% 1.2–2.2% a
3–6 months 0.48% 0.22–0.75% a
6–9 months 0.48% 0.01–1.1% b
9–12 months 0.59% 0.07–1.1% b
12–15 months 0.12% 0.00–0.35% b
15–18 months 0.36% 0.00–0.76% b
Major bleed risk per cycle a
0–3 months 0.41% 0.170.65% a
3–6 months 0.15% 0.00–0.30% a
Annual rate beyond 6 months 0.24% 0.00–0.57% b
CRNM bleed risk per cycle a
0–3 months 2.65% 2.04–3.26% a
3–6 months 1.20% 0.78–1.61% a
Annual rate beyond 6 months 3.00% 1.82–4.12% b
Adverse event related
discontinuation (not related
to bleeding and VTE)
a
0–6 months 4.87% 4.05–5.68% a
Annual rate beyond 6 months 6.67% 4.98–8.35% b
Distribution of recurrent VTE events
VTE-related death–on treatment 21.54% (28) a
Recurrent PE–on treatment 37.69% (49) a
Recurrent DVT–on treatment 40.77% (53) a
VTE-related death–off treatment 11.88% (12) b
Recurrent PE–off treatment 24.75% (25) b
Recurrent DVT–off treatment 63.37% (64) b
Distribution of major bleed events
Fatal bleed–on treatment 13.46% a
Non-fatal IC bleed–on treatment 13.97% a
Non-fatal non-IC bleed–on treatment
86.03% a
Fatal bleed–off treatment 13.46% b
Non-fatal IC bleed–off treatment 13.97% b
Non-fatal non-IC bleed–off treatment
86.03% b
Chronic thromboembolic pulmonary
hypertension (patients with PE)
(rate per 2.1 years)
1.25% 0.03–2.46% [24]








aData on file: Secondary Analysis of AMPLIFY (CV185-056) to Support Apixaban Cost
Effectiveness Modeling for the Indication of Treatment of Deep Vein Thrombosis
and Pulmonary Embolism in Venous Thromboembolisim (OR APIX 025). 2014
bData on File: Secondary Analysis of AMPLIFY-EXT (CV185-057) to Support
Apixaban Cost Effectiveness Modelling for the Extended Treatment of Deep
Vein Thrombosis and Pulmonary Embolism in Venous Thromboembolisim (OR
APIX 026). 2014
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bleed or CTEPH), the patient’s utility value was updated
and applied for the rest of their lifetime. Patients who
moved to the death state were assigned a utility of 0. In
addition to event-related decrements, it was assumed that
anticoagulation use would have a negative impact on the
health-related quality of life of patients who were on treat-
ment. Utility values and their sources are detailed in
Table 3.
Health and cost outcomes were discounted at 3.5% per
annum and the model had a lifetime time horizon [45].
Analyses
The base-model measured benefits in terms of LYs, QALYs,
and costs accumulated over the time horizon of the model.
The relative clinical benefit of apixaban versus LMWH/
VKA was assessed using the incremental cost-effectiveness
ratio (ICER), to ascertain whether the benefit gained was
obtained at a cost less than the UK payers’ usual
willingness-to-pay threshold of £20,000 per QALY [45].
One-way sensitivity analyses were conducted to evaluate
the robustness of the model results and conclusions in re-
lation to uncertainties in key model inputs, and to assess
how the model outcomes varied in relation to changes in
model parameters. Probabilistic sensitivity analysis was
conducted to account for the statistical uncertainty in par-
ameter estimates. Each parameter included in the model
was assigned a probability distribution according to its
mean value and 95% confidence interval. In each probabil-
istic sensitivity analysis run, a value was sampled from the
probability distribution of each parameter and used to
generate a corresponding pair of incremental QALYs and
incremental costs. The probabilistic sensitivity analysis
was run for over 2000 simulations, thereby producing
2000 pairs of incremental QALYs and costs that took into
account the distribution of potential values in the input
parameter as dictated by their confidence intervals. These
pairs of QALYs and costs were then used to determine the
probability of cost-effectiveness.
In addition to the above, and due to the uncertainty
about the duration of treatment, a scenario analysis was
conducted to assess how the cost-effectiveness of apixa-
ban changed when treatment was extended over lifetime.
To do this, the duration of treatment in the model was
varied for initial plus extended apixaban from 18 months
to indefinite treatment and compared to the following:
 Initial treatment with LMWH/VKA for 6 months
without altering the duration of treatment.
 Initial plus extended treatment with LMWH/VKA
over an indefinite duration.
Results
Base-case analysis (Table 4)
The evaluation in the current study predicted that, com-
pared to 6 months of LMWH/VKA followed by no treat-
ment, initial plus extended treatment with apixaban (as
studied in the AMPLIFY trials) would lead to 62 fewer
recurrent VTEs and VTE-related deaths, 13 fewer major
bleeds, and 28 fewer CRNM bleeds over the lifetimes of
1000 treated patients. Compared to initial plus extended
treatment with LMWH/VKA, apixaban was projected to
lead to 26 fewer major bleeds and 111 fewer CRNM
bleeds but, also, an additional 6 recurrent VTEs and
VTE-related deaths. The increase in the number of re-
current events was attributed to a greater treatment ef-
fect for VKA in the extended period.
Regardless of treatment duration for LMWH/VKA
(i.e., initial only or initial plus extended), apixaban treat-
ment yielded lower per-patient event costs (savings of
£145 and £101, respectively) and lower per-patient mon-
itoring and administration costs (savings of £200 and
£385, respectively). However drug acquisition costs were
higher for patients treated with apixaban in both ana-
lyses (incremental costs of £333 for initial only and
£1023 for initial plus extended).












Recurrent VTE and VTE-related death 1.18 0.83–1.66 5.33 3.02–9.40 0.42 0.16–1.06
Major bleed 3.26 1.84–5.79 2.07* 0.38–11.24 7.7 1.09–76.40
CRNM bleed 2.09 1.66–2.63 0.78 0.43–1.40 3.84 1.55–9.38
Other treatment discontinuation 1.07§ 0.85–1.35§ - 1.33 0.75–1.87
*Absolute event rates for major bleed, apixaban: 0.0024, placebo: 0.0048




cNMA (presented in the Additional file 2)
§Data on file: Secondary Analysis of AMPLIFY (CV185-056) to Support Apixaban Cost Effectiveness Modeling for the Indication of Treatment of Deep Vein
Thrombosis and Pulmonary Embolism in Venous Thromboembolisim (OR APIX 025). 2014
Lanitis et al. BMC Health Services Research  (2017) 17:74 Page 6 of 14
Table 3 Costs and Utilities
Mean Confidence Interval Description Source
Anticoagulant
Daily cost of apixaban
(initial period)a
£4.39 [36]
Daily cost of apixaban (prolonged
and extended)a
£2.20 [36]
Daily cost of low-molecular-weight heparin
(LMWH)/vitamin K antagonists (VKA)
(initial period)b
£9.02 [36]




One off cost for self-injection education
(applied to all patients)
£17.50 £12.25–£22.75 [35]
Administration (for patients unable to
self-inject)
£9.04 £6.33–£11.75 [35]




Average INR monitoring cost Assumption; NICE TA261 MS; NHS reference costs 2011/12,
Outpatient procedures; 324 Anticoagulant Service
[38, 39]
First 3 months £122.18
Subsequent 3 months £58.72
VTE events
DVT £389.72 £272.80–£506.64 NICE TA261 MS; NICE CG92, NHS reference costs 2011/2012;
QZ20Z, RA24Z, RA08A, RA60A, DAPF, 180
[38, 39]
PE or VTE-related death £1340.41 £938.29–£1742.54 NICE TA261 MS; NICE CG92, NHS reference costs 2011/2012;
DZ09A,DZ09B,DZ09C, RA24Z, RA08A, RA60A, DAPF, 180
[38, 39]
IC bleed (acute care) £2760.57 £2017.43–£3252.62 NHS reference costs 2011/2012; AA23A; AA23B [38]
IC bleed (maintenance) £4387.76 £3685.78–£5107.61 NHS reference costs VC04Z [38]
IC bleed (long-term) £672.53 £473.01–£894.93 [54]
CTEPH (acute care) £1888.23 £1379.02–£2225.48 NHS reference costs 2011/2012; AA23A; AA23B [38]
CTEPH (long-term) £4182.56 £2927.79–£5437.33 [43]
Non-IC major bleed £1043.26 £785.90–£1192.06 NHS reference costs 2011/2012; FZ24A-C; FZ38D-F; FZ43A-C [38]
CRNM bleed £133.56 £113.86–£147.78 NHS reference costs 2011/2012; VB07Z
PTS £18.00 £12.60–£23.40 [35]
Utilities
Utility estimates
IC bleed (acute care) 0.3300 0.140–0.530 30 days [41]
CTEPH (acute care) 0.6500 0.400–0.890 30 days [55]
Utility decrements
Apixaban 0.0020 0.000–0.0060 Whilst on treatment [10]
LMWH/VKA 0.0130 0.000–0.0047 Whilst on treatment [10]
DVT 0.1100 0.00–0.31 30 days [41]
PE 0.3200 0.09–0.59 30 days [41]
Non-IC bleed 0.3000 0.09–0.460 30 days [41]
CRNM bleed 0.0054 0.00–0.0195 2 days [42]
PTS 0.0700 0.00–0.24 Throughout [20]
a4 × * 5 mg (induction), 2 × *5 mg (long-term), 2 × *2.5 mg (extended)
b300 mg multi-dose vial, price calculated based on patient weight of 84.6 kg of LMWH (induction), 1 × * 1 mg and 1 × * 5 mg of warfarin (long-term)
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On average, a patient treated with apixaban accumu-
lated 0.110 and 0.046 additional LYs as compared to ini-
tial treatment with LMWH/VKA and to initial plus
extended treatment with LMWH/VKA, respectively.
This translated to 0.101 and 0.063 additional QALYs
compared to a patient treated with LMWH/VKA for ini-
tial or initial plus extended treatment, respectively.
These results led to an ICER of £6692 per QALY
gained as compared to initial treatment with LMWH/
VKA and an ICER of £8528 as compared to initial plus
extended treatment with LMWH/VKA. The ICER’s indi-
cate that initial plus extended treatment with apixaban is
a cost-effective alternative to treatment with LMWH/
VKA regardless of whether or not the latter is given for
an extended period.
One-way sensitivity analysis
Figure 2a and b present the results of the sensitivity ana-
lyses of the evaluation of initial plus extended treatment
with apixaban versus initial or initial plus extended treat-
ment with LMWH/VKA, respectively. These figures
(known as ‘tornado diagrams’) show the 15 parameters
that had the greatest effect on the ICERs arranged in de-
scending order of such influence.
The results showed that incremental costs for apixa-
ban versus initial and initial plus extended LMWH/VKA
varied between £349 and £1008 and between £207 and
£866, respectively, whilst incremental QALYs varied be-
tween 0.056 and 0.136 and 0.038 and 0.308, respectively.
This resulted in ICERs varying between £3441 and
£12,139 per QALY gained as compared to initial
treatment with LMWH/VKA and between £327 and
£15,132 per QALY gained as compared to initial plus ex-
tended treatment with LMWH/VKA.
When compared to initial treatment with LMWH/
VKA (Fig. 2a), the most influential parameters were
starting age, cost associated with apixaban, and the per-
centage of VTE-related deaths amongst recurrent VTEs.
As compared to initial plus extended treatment with
LMWH/VKA, the most influential parameters were rela-
tive risk of major bleeding versus apixaban for patients
treated with VKA for an extended period, cost associated
with apixaban, and the rate of major bleeding for pa-
tients treated with apixaban (Fig. 2b).
In both analyses, no scenario tested in the one-way
sensitivity analysis resulted in an ICER above £20,000
per QALY gained. Therefore, the conclusion that apixa-
ban is cost-effective is robust even when considering all
plausible ranges of values of individual parameters.
Probabilistic sensitivity analysis
Results of the probabilistic analysis are depicted in
terms of a cost-effectiveness acceptability curve, which
shows the probability that a treatment is the most
cost-effective alternative over a range of willingness-
to-pay thresholds. At a willingness-to-pay threshold of
£20,000 (denoting cost-effectiveness), initial plus ex-
tended treatment with apixaban had a 94% probability
of being the most cost-effective treatment option over
initial LMWH/VKA or initial plus extended LMWH/
VKA. Based on these results, it appears that apixaban
is a better treatment choice, economically speaking,
Table 4 Deterministic Results
Apixaban LMWH/VKA/Placebo Difference Apixaban LMWH/VKA Difference
Number of events
(total population)
Recurrent VTE and VTE-related death 514 577 −62 514 508 6
VTE-related death 63 71 −8 63 63 0
Recurrent PE 130 146 −16 130 129 1
Recurrent DVT 321 359 −39 321 316 5
Major bleeds 123 136 −13 123 149 −26
CRNM bleed 603 631 −28 603 714 −111
Treatment discontinuation due to adverse events 109 58 51 109 139 −30
Costs
Anticoagulant costs £1121 £98 £1023 £1121 £98 £1023
Monitoring and administration costsa £63 £261 -£200 £63 £446 -£385
Event-related costs £4069 £4214 -£145 £4069 £4170 -£101
QALYs 8.488 8.386 0.101 8.488 8.425 0.063
Life-years 10.421 10.311 0.110 10.421 10.375 0.046
Cost per QALY gained £6692 £8528
aMonitoring costs observed in the apixaban arm were attributed to the use of LMWH/VKA in patients who had a recurrent VTE event beyond the specified
apixaban treatment period
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over LMWH/VKA (initial, or initial plus extended) at
any willing-to-pay threshold above about £8000 per
QALY gained (Fig. 3).
Scenario analysis of indefinite treatment
Evaluation of initial plus extended treatment with apixa-
ban against alternative treatment durations demon-
strated that the cost-effectiveness of apixaban is durable
regardless of treatment duration for apixaban or
LMWH/VKA. The cost associated with apixaban in-
creases over indefinite treatment, as do health benefits.
Although the base-case analysis versus initial plus ex-
tended LMWH/VKA suggests more VTE recurrences
would occur in apixaban-treated patients, as a result of
the favourable treatment effect of VKA in the extended
period, this finding reversed when an indefinite treat-
ment duration was assessed. Since apixaban’s safer
bleeding profile allowed patients to remain on treatment
for longer than they did VKA therapy, apixaban was pre-
dicted to prevent more recurrent VTE events over an in-
definite duration.
Discussion
This study assessed the cost-effectiveness in patients with
VTE of initial plus extended treatment with apixaban ver-
sus LMWH/VKA provided either for initial treatment
only, or for initial plus extended treatment. It demon-
strated there are substantial benefits to extending treat-
ment, with apixaban providing more health benefits that
are cost-effective in comparison to extension with VKA.
Our analysis highlighted that initial plus extended treat-
ment with apixaban was superior to treatment with
LMWH/VKA in reducing the number of bleeding events
over a patient’s lifetime, regardless of the duration for
which LMWH/VKA was provided. The small net reduc-
tions in major bleeds and CRNM bleeds when compared
to the initial treatment with LMWH/VKA reflects the fact
that apixaban carries a lower risk of bleeding than does
LMWH/VKA in the first 6 months of treatment, and that,
compared with no treatment, it carries essentially no
added risk of major bleeding (0.24% vs. 0.48% with no
treatment) and only a small increase in the risk of CRNM
bleeding (3.00% vs. 2.30%) [13]. The advantage with
Fig. 2 a One-way Sensitivity Analysis versus Initial LMWH/VKA. b One-way Sensitivity Analysis versus Initial plus Extended LMWH/VKA. The tornado
diagrams (Fig. 2a and b) present the results of the deterministic sensitivity analyses and depict the key parameters that had the greatest impact
on the ICER. The boxes to the right and left of the tornado diagram represent the range tested for the parameter detailed in the description.
*The variation in the unit cost associated with apixaban corresponds to a range of the daily cost associated with apixaban of £3.07-£5.71 in the
initial period and £1.54-£2.85 in the prolonged and extended period
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regards to bleeding effects was magnified when apixaban
was compared to initial plus extended LMWH/VKA, in
line with apixaban’s better bleeding profile than VKA
when these two options have been compared indirectly
for extended treatment [46]. Our analysis demonstrated
an advantage for initial plus extended apixaban over initial
treatment with 6 months of LMWH/VKA in preventing
recurrent VTE events. However, when VKA treatment
was used for an additional 12 months that is for a similar
duration to apixaban, our analysis projected that it would
be associated with slightly fewer VTE events than would
apixaban. This effect was attributed to a slight advantage
for VKA over apixaban in preventing recurrent VTE
events in the extended period. This net increase in recur-
rent VTE events with apixaban was however offset by the
reduction in bleeding events. Subsequently, the net reduc-
tions in clinical events with apixaban treatment as com-
pared to either initial or initial plus extended LMWH/
VKA were projected to result in an increased life expect-
ancy and quality-adjusted life expectancy. These gains in
health outcomes were accompanied by reductions in
event-related costs and monitoring costs, but increased
drug acquisition costs for apixaban which led to an overall
increase in total costs. The ICER for initial plus extended
treatment of apixaban versus initial LMWH/VKA was
£6692 per QALY gained. When VKA was extended for
12 months post initial LMWH/VKA, the ICER was £8528
per QALY gained. The ICERs in both cases are below the
commonly accepted threshold of £20,000 per QALY
gained, [45] and so apixaban should be considered as a
cost-effective alternative to LMWH/VKA in both
scenarios.
In our analysis, we examined apixaban for 18 months
and LMWH/VKA for 6 or 18 months, in line with treat-
ment durations in clinical trials [12, 13]. However, the
appropriate duration of anticoagulant treatment has
been a source of clinical uncertainty. Guidelines on the
duration of LMWH/VKA therapy suggest that patients
should be treated for at least 3 months, and should be
extended to at least 6 months in case of unprovoked
VTE or indefinitely in patients with certain risk factors.
In reality, the duration of treatment applied in clinical
practice varies [4–7]. Therefore given the absence of an
established duration of treatment for VTE patients, we
used the clinical trial durations in our base case and
conducted scenario analyses to determine the impact of
using apixaban and LMWH/VKA over a lifetime dur-
ation. Compared with initial or initial plus extended life-
long treatment with LMWH/VKA, use of apixaban for
the rest of a patient’s life (i.e., regarding VTE as a
chronic condition) resulted in a cost-effectiveness esti-
mate of £13,107 and £16,944 per QALY gained, respect-
ively. Although the base base-case analysis comparison
with initial plus extended LMWH/VKA predicted a
higher number of VTE recurrences for apixaban, when
treatment duration of both treatments was increased to
lifetime, apixaban treatment was projected to lead to
fewer VTE events than would lifetime LMWH/VKA.
Patients on apixaban experienced far fewer major
bleeds than did those on VKA, which allowed them to
stay on treatment longer. As a result, patients on apixa-
ban for a lifelong duration experienced fewer recurrent
VTEs, despite the better efficacy associated with VKA in
the extended periods. The assumption that 52.7% of pa-
tients discontinued treatment after experiencing a major
bleeding event was based on findings from AMPLIFY
and is comparable to that adopted in earlier models (e.g.
40%, [15] 50% [47]) as observed in EINSTEIN. This con-
clusion held when one-third of patients or more were
assumed to discontinue treatment after a major bleed.
The improved safety of apixaban projected by the model































Willingness to pay per QALY gained
Apixaban Acute and extended LMWH/VKA Acute LMWH/VKA
Fig. 3 Cost-effectiveness Acceptability Curve. Figure 3 shows the probability of an intervention being the most cost-effective alternative at various
willingness-to to-pay thresholds, given the uncertainty surrounding inputs
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extended treatment can be clinically beneficial and cost-
effective, thus, further challenging the current suggestion
that there is clinical equipoise surrounding the use of ex-
tended anticoagulation.
Our model builds upon a foundation of structural simi-
larities to earlier cost-effectiveness analyses that have also
modelled VTE and bleeding events and the impact of anti-
coagulant treatment at several treatment durations [14,
15]. However, our projected QALYs are lower than those
estimated with earlier models. This can be attributed to
the fact that our model accounted for increased mortality
associated with VTE, in addition to its explicit modelling
of the excess mortality attributable to recurrent VTE and
bleeding. This approach is consistent with evidence from
retrospective studies showing excess mortality in patients
who develop VTE, even after adjusting for the increase as-
sociated with recurrences and bleeding [32]. Also, our
model accounted for increased risks of bleeding with
aging [30]. This was in contrast to earlier models that as-
sumed patients with VTE who do not experience any
other events follow the mortality patterns of the general
population, and which did not take into account the long-
term impact of bleeding events [14, 15]. Had we utilised
the same assumptions, the benefits associated with apixa-
ban would have been higher due to longer life expectancy
and increasing QALY gains to 0.146 and 0.081 compared
with a 6-month and an 18-month treatment duration for
LMWH/VKA, respectively, with corresponding ICERs of
£6155 and £4134 per QALY gained. Our analysis utilised
conservative inputs favouring comparators (for example,
lower monitoring costs than those employed in earlier
analyses), so the benefits of apixaban may be even greater
than shown in our analysis [39]. In addition recent re-
search has suggested that the true incidence of symptom-
atic CTEPH may be higher than the rate used in this
analysis (4.4%; 95% CI 2.0–9.3 vs. 1.25%; 95% CI 0.03–
2.46%, respectively) and therefore the reduction of
CTEPH caused by apixaban anticoagulation may be even
more pronounced [48]. Finally the recent reductions in
the price associated with apixaban in the UK, would have
resulted in even more favourable estimates of cost-
effectiveness, further enhancing our conclusions that apix-
aban is a cost-effective alternative to LMWH/VKA.
Our study has a number of strengths. It is the first to
examine the cost-effectiveness of apixaban for the treat-
ment and prevention of VTE recurrence. In addition, we
conducted scenario analyses to determine the impact of
apixaban over varying treatment durations, thus, allowing
clinicians to understand the overall health economic out-
comes of the drug. Our analysis employs data from both
initial-treatment and extended-treatment trials, [12, 13]
thus, considering the whole of the available evidence base
to project the potential impact of the introduction of apixa-
ban. This serves as both a strength and limitation in our
analysis for several reasons. In a controlled clinical trial set-
ting, patients may receive improved care and exhibit en-
hanced adherence to the drug. Thus, the observed efficacy,
safety, and tolerability may not reflect outcomes in the real
world. In addition, AMPLIFY-EXT (which compared apix-
aban versus no treatment after initial LMWH/VKA was
completed) reflects a patient population for whom the ben-
efits of extended anticoagulation were uncertain (clinical
equipoise), specifically excluding patients who were indi-
cated for long-term anticoagulation. The populations stud-
ied in AMPLIFY and AMPLIFY-EXT therefore differ in
terms of inclusion criteria, potentially excluding a propor-
tion of the VTE population in the extended phase. How-
ever the trial characteristics were similar in other respects,
and the approach of combining AMPLIFY and AMPLIFY-
EXT data to determine apixaban’s cost-effectiveness over
time has been accepted by the National Institute for Health
and Care Excellence Appraisal Committee [49].
A further caveat to our analysis stems from the absence
of head-to-head data for apixaban versus VKA in the ex-
tended period. Relative treatment effects were obtained by
means of an NMA. However, this analysis did not control
for the differences in patient baseline characteristics or
key differences in the populations included in the trials.
For example, out of the four VKA trials included in the
analysed network, REMEDY [27] specifically included pa-
tients at high risk of VTE previously treated for 3–12
months, and LAFIT [4] and the WODIT [28, 29] trials in-
cluded patients previously treated for 3 months, excluding
those who had an indication for continuing oral anticoa-
gulation therapy. AMPLIFY-EXT enrolled a population of
patients previously treated for 6–12 months for whom
there was clinical equipoise about the continuation of
anticoagulation therapy [13]. Of note, shorter duration of
previous anticoagulation is associated with increased risk
of recurrent VTE [23]. So the differences in prior duration
of treatment, with this being lower in the VKA trials, and
the population inclusion criteria of the VKA trials, collect-
ively suggest that the aggregation of VKA trials could
result in the focus being on a higher-risk population. This
could allow for the possibility of greater absolute risk re-
ductions being suggested for VKA therapy in comparison
to drugs such as apixaban that were evaluated in popula-
tions of patients at clinical equipoise with a longer prior
treatment duration. We therefore believe that the limita-
tions associated with the NMA make for conservative esti-
mations of apixaban’s benefits, and we believe that the
analyses we used represent the best available evidence in
the absence of head-to-head trials. Moreover, the NMA
used in this analysis is largely consistent with previously
published NMAs [46].
Nonetheless the applicability of comparative data, de-
rived from the NMA, to a real world setting is subject to
additional uncertainty. Studies conducted in atrial
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fibrillation have suggested that a lower rate of major
bleeding is observed in patients who are well controlled
with VKA [50]. In addition emerging tools to assess
which patients would likely have good time in thera-
peutic range with VKA treatment, could aid clinicians to
identify which patients would do well on warfarin [51].
Reducing the relative risk of major bleeding for LMWH/
VKA to the lowest estimate reported in real world stud-
ies [52, 53] (1.62 as compared to 3.33 and 7.70 in the
first 6 months and beyond 6 months) did not alter the
conclusions of our analysis. Apixaban remained cost-
effective at thresholds below £30,000 per QALY gained.
Several other limitations are associated with our ana-
lysis, resulting from the modelling approach or other in-
put data. The Markov cohort approach adopted is
memory-less, in that, at any point in time, the risk of fu-
ture events can only depend on the present state of pa-
tients, rather than the sequence of events that preceded
it. Therefore due to the adopted approach, and for the
sake of parsimony, we did not track or model any fur-
ther VTE recurrences after the development of either IC
bleeds or CTEPH. However, the expected cost and utility
attempted to capture worse morbidity over the long-
term and may implicitly account for future VTEs and
bleeds. We also did not account for increased risk of
additional recurrent VTEs once patients experienced a
recurrent event. This assumption may be unfavourable
to apixaban as compared to initial treatment with
LMWH/VKA or favourable as compared to initial plus
extended LMWH/VKA, given the reductions/increases
observed in recurrent VTE events with apixaban treat-
ment. However, sensitivity analysis that varied the costs
and utilities of recurrent VTE events (which could be
considered to reflect changes in the rates of recurrent
VTEs) did not alter the conclusions of our evaluation.
Finally, several utility values were available for the health
states included in the model. In our analysis, we attempted
to use UK EQ-5D values where possible, but these were
not available for all health states. Thus, utility values were
obtained from several sources and may not be specific to a
UK population. Of note, however, sensitivity analysis
around the base-case utility values did not alter the con-
clusions of the evaluation. Similarly, results from one-way
and probabilistic sensitivity analyses, in which all parame-
ters that could be subject to uncertainty were varied over
their confidence intervals, demonstrated that apixaban
treatment was cost-effective regardless of the duration of
treatment of with LMWH/VKA.
Conclusions
The comprehensive assessment of the effects and costs of
apixaban in this study predicted that initial plus extended
treatment with apixaban for patients with VTE was cost-
effective in the UK compared with LMWH/VKA used
either for initial treatment only or initial plus extended
treatment. Specifically, apixaban could offer favourable
health benefits at a marginal increase in costs. The findings
in our study could help clinicians and payers make in-
formed decisions in the best interest of patients with VTE,
particularly when considering extended anticoagulant
treatment.
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